HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral cimetidine in reflux esophagitis: a double blind controlled trial.

Abstract
The efficacy of cimetidine (1.6 g per day) was evaluated using a double blind placebo-controlled trial in 24 patients with moderate or severe peptic reflux esophagitis. The results show that cimetidine is superior to placebo when using endoscopic and histological criteria. Improved patient symptomatology and lower antacid comsumption failed to reach statistical significance. No change in the abnormally low lower esophageal sphincter pressure was observed at the end of the trial. No clinical side effects or significant biochemical changes were noted during the trial.
AuthorsE Wesdorp, J Bartelsman, K Pape, W Dekker, G N Tytgat
JournalGastroenterology (Gastroenterology) Vol. 74 Issue 5 Pt 1 Pg. 821-4 (May 1978) ISSN: 0016-5085 [Print] United States
PMID346430 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Guanidines
  • Placebos
  • Cimetidine
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Cimetidine (administration & dosage, therapeutic use)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Esophagitis, Peptic (drug therapy, pathology)
  • Esophagoscopy
  • Female
  • Guanidines (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Placebos

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: